Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases
Phillip G. Febbo, Anne‐Marie Martin, Howard I. Scher et al. · Clinical Pharmacology & Therapeutics · 2020
Peer Reviewed
Cited by 48 works. doi:10.1002/cpt.1747 Open-access PDF
Authors
- Phillip G. Febbo
- Anne‐Marie Martin
- Howard I. Scher
- J. Carl Barrett
- Julia A. Beaver
- Paul J. Beresford
- Gideon Michael Blumenthal
- Kelli S. Bramlett
- Carolyn C. Compton
- Ryan Vance Dittamore
- David A. Eberhard
- Daniel L. Edelstein
- James H. Godsey
- Andrew Gruen
- Sean E. Hanlon
- James B Hicks
- Daniel H. Hovelson
- Melanie A. Hullings
- Donald Joseph Johann
- Justin H. Johnson
References
- Sources of Bias in Specimens for Research About Molecular Markers for Cancer
- Validation of Analytic Methods for Biomarkers Used in Drug Development
- Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
- Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine
- Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium
- Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development
- Impact of Preanalytic Factors on the Design and Application of Integral Biomarkers for Directing Patient Therapy
- Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy
- Development and Use of Integral Assays in Clinical Trials